Caladrius Biosciences Company Profile (NASDAQ:CLBS)

Analyst Ratings

Consensus Ratings for Caladrius Biosciences (NASDAQ:CLBS) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $3.25 (524.88% upside)

Analysts' Ratings History for Caladrius Biosciences (NASDAQ:CLBS)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2016Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Rodman & RenshawUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2016HC WainwrightUpgradeNeutral -> Buy$1.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015WBB SecuritiesReiterated RatingBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Benchmark Co.DowngradeBuy -> Hold$12.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015MLV & Co.Initiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2015Oppenheimer Holdings Inc.Initiated CoverageOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.31)($0.31)$4.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015($0.42)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014($0.41)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.28)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.40)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Caladrius Biosciences (NASDAQ:CLBS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Caladrius Biosciences (NASDAQ:CLBS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Caladrius Biosciences (NASDAQ:CLBS)
DateHeadline
07/27/16 08:08 AMCaladrius Biosciences Announces 1-for-10 Reverse Split - [at noodls] - BASKING RIDGE, N.J., July 27, 2016 - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ('Caladrius' or the 'Company'), a cell therapy company combining an industry-leading development and manufacturing services ...
07/23/16 07:31 AMEquity Roundup: Stock Performance Focus on Caladrius Biosciences Inc (NASDAQ:CLBS) - Press Telegraph
07/22/16 10:57 AMCaladrius Biosciences Inc (NASDAQ:CLBS) Stock Technicals at Critical Inflection Point - CML News
07/21/16 12:52 PMETF’s with exposure to Caladrius Biosciences, Inc. : July 21, 2016 -
07/20/16 10:55 AMCaladrius Biosciences, Inc. (NasdaqCM:CLBS) Fundamental Star Rating Report - CML News
07/20/16 10:55 AMBroker Outlook For Caladrius Biosciences, Inc. (CLBS) - Fiscal Standard
07/18/16 03:27 PMCaladrius Biosciences Inc (NASDAQ:CLBS) Wall Street Analyst Recommendation Outlook - TGP
07/15/16 11:31 AMNew Broker Ratings For Caladrius Biosciences, Inc. (CLBS) - FTSE News
07/14/16 08:39 AMCaladrius Biosciences Inc Stock Momentum Hits Extreme Weakness - CML News
07/13/16 08:38 PMCaladrius Biosciences Inc (NASDAQ:CLBS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 07:29 AMTime to Sell Caladrius Biosciences Inc After The Completion of This Bearish Multiple Bottom Chart Pattern? - Consumer Eagle
07/07/16 11:02 AMCan Caladrius Biosciences Inc (NASDAQ:CLBS) Improve on the Earnings Front? - Engelwood Daily
07/07/16 11:02 AMCaladrius Biosciences, Inc. (CLBS) Current Analyst Ratings - Fiscal Standard
07/07/16 11:02 AMCaladrius Biosciences to Present at Upcoming July Conferences - GlobeNewswire (press release)
07/07/16 06:31 AMCaladrius Biosciences to Present at Upcoming July Conferences - [at noodls] - BASKING RIDGE, N.J., July 7, 2016 - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ('Caladrius' or the 'Company'), a cell therapy company combining an industry-leading development and manufacturing services ...
07/05/16 07:58 AMBroker Outlook For The Week Ahead Caladrius Biosciences, Inc. (CLBS) - Fiscal Standard
06/30/16 08:42 PMCheck on Unusual Volume for: Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Engelwood Daily
06/29/16 08:19 PMCaladrius Biosciences Incorporated (NASDAQ:CLBS) Shorts Decreased by 30.43% After Short Covering - Engelwood Daily
06/29/16 11:22 AMCovering the Bases on Caladrius Biosciences Inc (NASDAQ:CLBS): Where is the Stock Going? - Press Telegraph
06/27/16 04:02 PMCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/27/16 06:41 AMCaladrius Biosciences SVP and President of PCT, Robert Preti, PhD, Named Chairman of the Alliance for Regenerative Medicine - [at noodls] - New York, June 27, 2016 - Caladrius Biosciences (Nasdaq: CLBS), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, a Caladrius company) with ...
06/23/16 03:51 PMCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/22/16 07:58 AMCaladrius Subsidiary, PCT, to Manufacture Phase 3 Cell Therapy Product for Kiadis Pharma
06/20/16 01:13 PMETF’s with exposure to Caladrius Biosciences, Inc. : June 20, 2016 -
06/19/16 03:03 PMThis Weeks Broker Views For Caladrius Biosciences, Inc. (CLBS) - Fiscal Standard
06/03/16 09:21 PMCaladrius Biosciences Inc (NASDAQ:CLBS) Stock Update & Estimates - Stock Tick Tock
06/03/16 02:13 PMETF’s with exposure to Caladrius Biosciences, Inc. : June 3, 2016 -
06/02/16 08:06 PMStock Review and Earnings Check on Caladrius Biosciences Inc (NASDAQ:CLBS) - HNN - Stock Review and Earnings Check on Caladrius Biosciences Inc (NASDAQ:CLBS)HNNCurrently, sell-side analysts are expecting Caladrius Biosciences Inc (NASDAQ:CLBS) to report quarterly EPS of $-0.15. The company's next earnings report is expected to be published on or around 2016-08-04 for the period ending on 2016-06-30.and more »
06/01/16 11:52 AMCaladrius Biosciences to Present at Upcoming June Conferences - GlobeNewswire (press release) - Caladrius Biosciences to Present at Upcoming June ConferencesGlobeNewswire (press release)BASKING RIDGE, N.J., June 01, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with ...
06/01/16 06:53 AMCaladrius Biosciences to Present at Upcoming June Conferences - [at noodls] - BASKING RIDGE, N.J., June 1, 2016 - Caladrius Biosciences, Inc. (NASDAQ: CLBS) ('Caladrius' or the 'Company'), a cell therapy company combining an industry-leading development and manufacturing services ...
05/31/16 03:18 PMShare Rating Focus on Caladrius Biosciences Inc (NASDAQ:CLBS) - HNN - Share Rating Focus on Caladrius Biosciences Inc (NASDAQ:CLBS)HNNPresently, Wall Street analysts have given a consensus stock rating of 2 on shares of Caladrius Biosciences Inc (NASDAQ:CLBS). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus ...and more »
05/29/16 05:05 PMPerformance at a Glance on Caladrius Biosciences, Inc. (NASDAQ:CLBS) - HNN - Performance at a Glance on Caladrius Biosciences, Inc. (NASDAQ:CLBS)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Caladrius Biosciences, Inc. (NASDAQ:CLBS)'s stock has performed at various points in its past ...and more »
05/26/16 05:20 PMEarnings Review and Stock Rundown for Caladrius Biosciences Inc (NASDAQ:CLBS) - Wall Street Hints and News - Earnings Review and Stock Rundown for Caladrius Biosciences Inc (NASDAQ:CLBS)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Caladrius Biosciences Inc (NASDAQ:CLBS ...and more »
05/26/16 09:50 AMCaladrius Biosciences, Inc. :CLBS-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 -
05/26/16 08:32 AMCaladrius Biosciences (CLBS) Enters Ovarian Cancer Treatment Patent License with AiVita Biomedical - StreetInsider.com - Caladrius Biosciences (CLBS) Enters Ovarian Cancer Treatment Patent License with AiVita BiomedicalStreetInsider.comCaladrius Biosciences, Inc. (Nasdaq: CLBS) announces that it has licensed to AiVita Biomedical, Inc. (“AiVita”) the exclusive global rights to its tumor cell/dendritic cell technology for the treatment of ovarian cancer. In return, Caladrius will ...and more »
05/26/16 06:47 AMCaladrius Biosciences Licenses Cell Therapy Technology for Ovarian Cancer and Subleases Irvine Facility to AiVita Biomedical - [at noodls] - BASKING RIDGE, N.J., May 26, 2016 - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ('Caladrius' or the 'Company'), a cell therapy company combining an industry-leading development and manufacturing services ...
05/15/16 05:40 PMNext Weeks Broker Price Targets For Caladrius Biosciences, Inc. (CLBS) - Share Trading News - Next Weeks Broker Price Targets For Caladrius Biosciences, Inc. (CLBS)Share Trading NewsCaladrius Biosciences, Inc. has a 50 day moving average of 0.70 and a 200 day moving average of 0.83. The stock's market capitalization is 36.01M, it has a 52-week low of 0.40 and a 52-week high of 3.47. The share price of the company (CLBS) was down ...and more »
05/14/16 12:04 PMCALADRIUS BIOSCIENCES, INC. Financials -
05/12/16 05:35 PMCaladrius Biosciences, Inc. (CLBS) Updated Broker Price Targets - Share Trading News - Caladrius Biosciences, Inc. (CLBS) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Caladrius Biosciences, Inc. (CLBS). The latest reports which are currently in issue on Thursday 12th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/12/16 05:35 PMCaladrius Biosciences' (CLBS) CLBS03 Receives FDA Orphan Drug Designation for T1D - StreetInsider.com - Caladrius Biosciences' (CLBS) CLBS03 Receives FDA Orphan Drug Designation for T1DStreetInsider.comCaladrius Biosciences, Inc. (Nasdaq: CLBS) announces that its product candidate CLBS03 (autologous expanded polyclonal regulatory T cells, or Tregs) for the treatment of recent-onset type 1 diabetes (“T1D”) was granted orphan-drug designation by the US ...and more »
05/12/16 04:27 PMCaladrius Biosciences Receives Orphan Drug Designation for CLBS03 to Treat Type 1 Diabetes - [at noodls] - BASKING RIDGE, N.J., May 12, 2016 - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ('Caladrius' or the 'Company'), a cell therapy company combining an industry-leading development and manufacturing services ...
05/10/16 10:39 PMConsensus Rating Review for Caladrius Biosciences Inc (NASDAQ:CLBS) - B.O.D.Y Confidential - Consensus Rating Review for Caladrius Biosciences Inc (NASDAQ:CLBS)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 2 on shares of Caladrius Biosciences Inc (NASDAQ:CLBS). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell ...and more »
05/09/16 05:26 PMCaladrius Biosciences to Present at Multiple Upcoming May Conferences - GlobeNewswire (press release) - Caladrius Biosciences to Present at Multiple Upcoming May ConferencesGlobeNewswire (press release)BASKING RIDGE, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a ...and more »
05/09/16 06:46 AMCaladrius Biosciences to Present at Multiple Upcoming May Conferences - [at noodls] - BASKING RIDGE, N.J., May 09, 2016 - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ('Caladrius' or the 'Company'), a cell therapy company combining an industry-leading development and manufacturing services ...
05/07/16 04:56 PMCaladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2016 Results - Earnings Call Transcript - Welcome to the Caladrius Biosciences 2016 First Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. Following managements prepared remarks, we will held a Q&A session [Operator Instructions] As a reminder ...
05/05/16 10:58 PMCaladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2016 Results - Earnings Call Transcript - Seeking Alpha - Caladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaWelcome to the Caladrius Biosciences 2016 First Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. Following managements prepared remarks, we will held a Q&A session [Operator Instructions] As a reminder ...Caladrius Biosciences Reports 2016 First Quarter Financial ResultsGlobeNewswire (press release)all 2 news articles »
05/05/16 05:48 PMEarnings Outlook on Caladrius Biosciences Inc (NASDAQ:CLBS) - B.O.D.Y Confidential - Earnings Outlook on Caladrius Biosciences Inc (NASDAQ:CLBS)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Caladrius Biosciences Inc (NASDAQ:CLBS)'s next earnings release which is expected to be posted on or around 2016-05-05. Sell-side research firms on Wall Street are expecting that the company will post EPS of ...and more »
05/05/16 05:48 PMCaladrius Biosciences Reports 2016 First Quarter Financial Results - GlobeNewswire (press release) - Caladrius Biosciences Reports 2016 First Quarter Financial ResultsGlobeNewswire (press release)BASKING RIDGE, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius”), a cell therapy company combining an industry-leading development and manufacturing services provider (through its subsidiary, PCT, ...and more »
05/05/16 04:43 PMCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure -
05/05/16 03:14 PMCaladrius Biosciences Reports 2016 First Quarter Financial Results - [GlobeNewswire] - Total Quarterly Revenues Increase 136% versus Prior Year. Conference Call Begins Today at 5:00 pm Eastern Time. BASKING RIDGE, N.J., May 05, 2016-- Caladrius Biosciences, Inc., a cell therapy company combining ...

Social

About Caladrius Biosciences

Caladrius Biosciences logoCaladrius Biosciences, Inc., formerly NeoStem, Inc., is a clinical-stage biopharmaceutical company. The Company's clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CSCs). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy), which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10, which has completed Phase I clinical trials. Under T Regulatory Cell Program, the Company is developing NBS03D, which is in the Phase I clinical trial stage.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLBS
  • CUSIP:
Key Metrics:
  • Previous Close: $0.52
  • 50 Day Moving Average: $0.5460
  • 200 Day Moving Average: $0.6168
  • P/E Ratio: N/A
  • P/E Growth: -0.0100
  • Market Cap: $30.70M
  • Beta: 1.28
  • Current Year EPS Consensus Estimate: $-0.77 EPS
  • Next Year EPS Consensus Estimate: $-0.36 EPS
Additional Links:
Caladrius Biosciences (NASDAQ:CLBS) Chart for Thursday, July, 28, 2016